Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 3634948, 10 pages
http://dx.doi.org/10.1155/2016/3634948
Review Article

Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders

1Department of Internal Medicine, Occupational Diseases Hypertension and Clinical Oncology, Wroclaw Medical University, Ulica Borowska 213, 50-556 Wrocław, Poland
2Research and Development Department, Integrated Cardiovascular Centre Provincial Specialist Hospital in Wroclaw (WROVASC), Ulica Kamieńskiego 73a, 51-124 Wrocław, Poland

Received 13 March 2016; Accepted 12 May 2016

Academic Editor: Carlos Rosales

Copyright © 2016 A. Janus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Mather, T. J. Anderson, and S. Verma, “Insulin action in the vasculature: physiology and pathophysiology,” Journal of Vascular Research, vol. 38, no. 5, pp. 415–422, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, and A. M. Zeiher, “Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation,” Nature, vol. 399, no. 6736, pp. 601–605, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. W. A. Hsueh and R. E. Law, “Insulin signaling in the arterial wall,” The American Journal of Cardiology, vol. 84, no. 1, pp. 21J–24J, 1999. View at Google Scholar · View at Scopus
  4. J.-A. Kim, M. Montagnani, K. K. Koh, and M. J. Quon, “Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms,” Circulation, vol. 113, no. 15, pp. 1888–1904, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. F. Youngren, “Regulation of insulin receptor function,” Cellular and Molecular Life Sciences, vol. 64, no. 7-8, pp. 873–891, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Inoue, B. Cheatham, R. Emkey, and C. R. Kahn, “Dynamics of insulin signaling in 3T3-L1 adipocytes. Differential compartmentalization and trafficking of insulin receptor substrate (IRS)-1 and IRS-2,” The Journal of Biological Chemistry, vol. 273, no. 19, pp. 11548–11555, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Taguchi and M. F. White, “Insulin-like signaling, nutrient homeostasis, and life span,” Annual Review of Physiology, vol. 70, pp. 191–212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. J. Withers, J. S. Gutierrez, H. Towery et al., “Disruption of IRS-2 causes type 2 diabetes in mice,” Nature, vol. 391, no. 6670, pp. 900–904, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Giraud, R. Leshan, Y.-H. Lee, and M. F. White, “Nutrient-dependent and insulin-stimulated phosphorylation of insulin receptor substrate-1 on serine 302 correlates with increased insulin signaling,” The Journal of Biological Chemistry, vol. 279, no. 5, pp. 3447–3454, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. B. A. Hemmings and D. F. Restuccia, “PI3K-PKB/Akt pathway,” Cold Spring Harbor Perspectives in Biology, vol. 4, no. 9, Article ID a011189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Miao, I. Skidan, J. Yang et al., “Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 46, pp. 20126–20131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Lawlor and D. R. Alessi, “PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?” Journal of Cell Science, vol. 114, part 16, pp. 2903–2910, 2001. View at Google Scholar · View at Scopus
  13. S. H. Snyder and S. R. Jaffrey, “Vessels vivified by Akt acting on NO synthase,” Nature Cell Biology, vol. 1, no. 4, pp. 95–96, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Avogaro, M. Albiero, L. Menegazzo, S. de Kreutzenberg, and G. P. Fadini, “Endothelial dysfunction in diabetes: the role of reparatory mechanisms,” Diabetes Care, vol. 34, no. 2, pp. S285–S290, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Hermann, B. Assmus, C. Urbich, A. M. Zeiher, and S. Dimmeler, “Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 2, pp. 402–409, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Morbidelli, S. Donnini, and M. Ziche, “Role of nitric oxide in the modulation of angiogenesis,” Current Pharmaceutical Design, vol. 9, no. 7, pp. 521–530, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. T. J. McCabe, D. Fulton, L. J. Roman, and W. C. Sessa, “Enhanced electron flux and reduced calmodulin dissociation may explain ‘calcium-independent’ eNOS activation by phosphorylation,” Journal of Biological Chemistry, vol. 275, no. 9, pp. 6123–6128, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. B. D. Manning and L. C. Cantley, “AKT/PKB signaling: navigating downstream,” Cell, vol. 129, no. 7, pp. 1261–1274, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. C. M. Taniguchi, B. Emanuelli, and C. R. Kahn, “Critical nodes in signalling pathways: insights into insulin action,” Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 85–96, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Rubinfeld and R. Seger, “The ERK cascade: a prototype of MAPK signaling,” Molecular Biotechnology, vol. 31, no. 2, pp. 151–174, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Ferri, V. Pittoni, A. Piccoli et al., “Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo,” The Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 3, pp. 829–835, 1995. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Rask-Madsen and C. R. Kahn, “Tissue–specific insulin signaling, metabolic syndrome, and cardiovascular disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 9, pp. 2052–2059, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Cusi, K. Maezono, A. Osman et al., “Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle,” Journal of Clinical Investigation, vol. 105, no. 3, pp. 311–320, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. M. S. Brown and J. L. Goldstein, “Selective versus total insulin resistance: a pathogenic paradox,” Cell Metabolism, vol. 7, no. 2, pp. 95–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon, “Cardiovascular actions of insulin,” Endocrine Reviews, vol. 28, no. 5, pp. 463–491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines in inflammation and metabolic disease,” Nature Reviews Immunology, vol. 11, no. 2, pp. 85–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. W. A. Hsueh and M. J. Quiñones, “Role of endothelial dysfunction in insulin resistance,” The American Journal of Cardiology, vol. 92, no. 4, pp. 10J–17J, 2003. View at Google Scholar · View at Scopus
  28. M. Montagnani, I. Golovchenko, I. Kim et al., “Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells,” The Journal of Biological Chemistry, vol. 277, no. 3, pp. 1794–1799, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Davignon and P. Ganz, “Role of endothelial dysfunction in atherosclerosis,” Circulation, vol. 109, no. 23, pp. III27–III32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. M. M. Hartge, T. Unger, and U. Kintscher, “The endothelium and vascular inflammation in diabetes,” Diabetes and Vascular Disease Research, vol. 4, no. 2, pp. 84–88, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Del Prato, “Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies,” Diabetic Medicine, vol. 26, no. 12, pp. 1185–1192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Musicki, M. F. Kramer, R. E. Becker, and A. L. Burnett, “Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 33, pp. 11870–11875, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. T. A. McGowan, S. R. Dunn, B. Falkner, and K. Sharma, “Stimulation of urinary TGF-β and isoprostanes in response to hyperglycemia in humans,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 2, pp. 263–268, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Gabriely, X. M. Yang, J. A. Cases, X. H. Ma, L. Rossetti, and N. Barzilai, “Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway,” Atherosclerosis, vol. 160, no. 1, pp. 115–122, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. D. L. Price, P. M. Rhett, S. R. Thorpe, and J. W. Baynes, “Chelating activity of advanced glycation end-product inhibitors,” Journal of Biological Chemistry, vol. 276, no. 52, pp. 48967–48972, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. D. R. Sell, R. H. Nagaraj, S. K. Grandhee et al., “Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia,” Diabetes/Metabolism Reviews, vol. 7, no. 4, pp. 239–251, 1991. View at Publisher · View at Google Scholar · View at Scopus
  37. J. L. Wautier and P. J. Guillausseau, “Advanced glycation end products, their receptors and diabetic angiopathy,” Diabetes and Metabolism, vol. 27, no. 5, pp. 535–542, 2001. View at Google Scholar · View at Scopus
  38. M. C. Gage, N. Y. Yuldasheva, H. Viswambharan et al., “Endothelium-specific insulin resistance leads to accelerated atherosclerosis in areas with disturbed flow patterns: a role for reactive oxygen species,” Atherosclerosis, vol. 230, no. 1, pp. 131–139, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. N. J. Hançer, W. Qiu, C. Cherella, Y. Li, K. D. Copps, and M. F. White, “Insulin and metabolic stress stimulate multisite serine/threonine phosphorylation of insulin receptor substrate 1 and inhibit tyrosine phosphorylation,” Journal of Biological Chemistry, vol. 289, no. 18, pp. 12467–12484, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Kaplan, M. Aviram, and T. Hayek, “Oxidative stress and macrophage foam cell formation during diabetes mellitusinduced atherogenesis: role of insulin therapy,” Pharmacology & Therapeutics, vol. 136, no. 2, pp. 175–185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. A. M. Briones, R. Aras-López, M. J. Alonso, and M. Salaices, “Small artery remodeling in obesity and insulin resistance,” Current Vascular Pharmacology, vol. 12, no. 3, pp. 427–437, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Van Puyvelde, T. Mets, R. Njemini, I. Beyer, and I. Bautmans, “Effect of advanced glycation end product intake on inflammation and aging: a systematic review,” Nutrition Reviews, vol. 72, no. 10, pp. 638–650, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Berg, L. Schreier, and V. Miksztowicz, “Circulating and adipose tissue matrix metalloproteinases in cardiometabolic risk environments: pathophysiological aspects,” Hormone Molecular Biology and Clinical Investigation, vol. 17, no. 2, pp. 79–87, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. A. R. Wende, J. D. Symons, and E. D. Abel, “Mechanisms of lipotoxicity in the cardiovascular system,” Current Hypertension Reports, vol. 14, no. 6, pp. 517–531, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Li, H. Li, Y. Bao, X. Zhang, and Y. Yu, “Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor-κB pathway in rat aorta,” International Journal of Cardiology, vol. 152, no. 2, pp. 218–224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Inoguchi, P. Li, F. Umeda et al., “High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells,” Diabetes, vol. 49, no. 11, pp. 1939–1945, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Mathew, E. Tay, and K. Cusi, “Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects,” Cardiovascular Diabetology, vol. 9, article 9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. R. G. Baker, M. S. Hayden, and S. Ghosh, “NF-κB, inflammation, and metabolic disease,” Cell Metabolism, vol. 13, no. 1, pp. 11–22, 2011. View at Publisher · View at Google Scholar
  49. S. E. Kahn, R. L. Hull, and K. M. Utzschneider, “Mechanisms linking obesity to insulin resistance and type 2 diabetes,” Nature, vol. 444, no. 7121, pp. 840–846, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. K. H. Jung, H. S. Choi, D. H. Kim et al., “Epigallocatechin gallate stimulates glucose uptake through the phosphatidylinositol 3-kinase-mediated pathway in L6 rat skeletal muscle cells,” Journal of Medicinal Food, vol. 11, no. 3, pp. 429–434, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. J.-A. Kim, M. Montagnani, K. K. Kwang, and M. J. Quon, “Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms,” Circulation, vol. 113, no. 15, pp. 1888–1904, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. X.-X. Zheng, Y.-L. Xu, S.-H. Li, X.-X. Liu, R. Hui, and X.-H. Huang, “Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials,” The American Journal of Clinical Nutrition, vol. 94, no. 2, pp. 601–610, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Rizza, R. Muniyappa, M. Iantorno et al., “Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 5, pp. E782–E792, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. K. M. Munir, S. Chandrasekaran, F. Gao, and M. J. Quon, “Mechanisms for food polyphenols to ameliorate insulin resistance and endothelial dysfunction: therapeutic implications for diabetes and its cardiovascular complications,” American Journal of Physiology—Endocrinology and Metabolism, vol. 305, no. 6, pp. E679–E686, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Uribarri, W. Cai, M. Peppa et al., “Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging,” Journals of Gerontology—Series A: Biological Sciences and Medical Sciences, vol. 62, no. 4, pp. 427–433, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Vlassara, W. Cai, J. Crandall et al., “Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15596–15601, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. N. J. Kellow and G. S. Savige, “Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review,” European Journal of Clinical Nutrition, vol. 67, no. 3, pp. 239–248, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Sofi, R. Abbate, G. F. Gensini, and A. Casini, “Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis,” The American Journal of Clinical Nutrition, vol. 92, no. 5, pp. 1189–1196, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Koloverou, K. Esposito, D. Giugliano, and D. Panagiotakos, “The effect of Mediterranean diet on the development of type 2 diabetes mellitus: a meta-analysis of 10 prospective studies and 136,846 participants,” Metabolism: Clinical and Experimental, vol. 63, no. 7, pp. 903–911, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Bouchonville, R. Armamento-Villareal, K. Shah et al., “Weight loss, exercise or both and cardiometabolic risk factors in obese older adults: results of a randomized controlled trial,” International Journal of Obesity, vol. 38, no. 3, pp. 423–431, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Esposito, M. I. Maiorino, M. Petrizzo, G. Bellastella, and D. Giugliano, “The effects of a Mediterranean diet on the need for diabetes drugs and remission of newly diagnosed type 2 diabetes: follow-up of a randomized trial,” Diabetes Care, vol. 37, no. 7, pp. 1824–1830, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. A. K. F. Wong, A. D. Struthers, A. M. J. Choy, and C. C. Lang, “Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones,” Heart Failure Clinics, vol. 8, no. 4, pp. 539–550, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. W. A. Hsueh and R. E. Law, “PPARγ and atherosclerosis effects on cell growth and movement,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 12, pp. 1891–1895, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart, “Peroxisome proliferator-activated receptor γ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor γ-dependent mechanisms,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1810–1816, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Natali and E. Ferrannini, “Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review,” Diabetologia, vol. 49, no. 3, pp. 434–441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. B. J. Davis, Z. Xie, B. Viollet, and M.-H. Zou, “Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase,” Diabetes, vol. 55, no. 2, pp. 496–505, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. M. R. Owen, E. Doran, and A. P. Halestrap, “Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain,” The Biochemical Journal, vol. 348, no. 3, pp. 607–614, 2000. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Foretz, B. Guigas, L. Bertrand, M. Pollak, and B. Viollet, “Metformin: from mechanisms of action to therapies,” Cell Metabolism, vol. 20, no. 6, pp. 953–966, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Dicker, “DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors,” Diabetes Care, vol. 34, supplement 2, pp. S276–S278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. J. E. Campbell and D. J. Drucker, “Pharmacology, physiology, and mechanisms of incretin hormone action,” Cell Metabolism, vol. 17, no. 6, pp. 819–837, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. International Nonproprietary Names for Pharmaceutical Substances (INN), “Recommended INN: list 61,” WHO Drug Information, vol. 23, no. 1, p. 66f, 2009. View at Google Scholar
  72. J. R. Ussher and D. J. Drucker, “Cardiovascular biology of the incretin system,” Endocrine Reviews, vol. 33, no. 2, pp. 187–215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. Ö. Erdogdu, D. Nathanson, Å. Sjöholm, T. Nyström, and Q. Zhang, “Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor,” Molecular and Cellular Endocrinology, vol. 325, no. 1-2, pp. 26–35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Liu, A. E. Dear, L. B. Knudsen, and R. W. Simpson, “A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules,” Journal of Endocrinology, vol. 201, no. 1, pp. 59–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Arakawa, T. Mita, K. Azuma et al., “Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4,” Diabetes, vol. 59, no. 4, pp. 1030–1037, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. Z. Shah, T. Kampfrath, J. A. Deiuliis et al., “Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis,” Circulation, vol. 124, no. 21, pp. 2338–2349, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. I. Hadjiyanni, K. A. Siminovitch, J. S. Danska, and D. J. Drucker, “Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells,” Diabetologia, vol. 53, no. 4, pp. 730–740, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Kassan, M. Galan, M. Partyka, M. Trebak, and K. Matrougui, “Interleukin-10 released by CD4+CD25+ Natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 11, pp. 2534–2542, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. A. R. Aroor, J. R. Sowers, S. B. Bender et al., “Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats,” Endocrinology, vol. 154, no. 7, pp. 2501–2513, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. W. B. White, C. P. Cannon, S. R. Heller et al., “Alogliptin after acute coronary syndrome in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 369, no. 14, pp. 1327–1335, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. B. M. Scirica, D. L. Bhatt, E. Braunwald et al., “Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 369, no. 14, pp. 1317–1326, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. L. Eriksson and T. Nyström, “Antidiabetic agents and endothelial dysfunction—beyond glucose control,” Basic and Clinical Pharmacology and Toxicology, vol. 117, no. 1, pp. 15–25, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Manrique, G. Lastra, M. Gardner, and J. R. Sowers, “The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress,” Medical Clinics of North America, vol. 93, no. 3, pp. 569–582, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. M. E. Pueyo, W. Gonzalez, A. Nicoletti, F. Savoie, J.-F. Arnal, and J.-B. Michel, “Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 645–651, 2000. View at Publisher · View at Google Scholar · View at Scopus
  85. J. M. Perkins and S. N. Davis, “The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 15, no. 2, pp. 147–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. G. Tocci, F. Paneni, F. Palano et al., “Angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials,” American Journal of Hypertension, vol. 24, no. 5, pp. 582–590, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. A. J. Scheen, “Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials,” Diabetes & Metabolism, vol. 30, no. 6, pp. 487–496, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Bosch, S. Yusuf, H. C. Gerstein et al., “Effect of ramipril on the incidence of diabetes,” The New England Journal of Medicine, vol. 355, no. 15, pp. 1551–1562, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. G. B. J. Mancini, G. C. Henry, C. Macaya et al., “Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing Endothelial Dysfunction) study,” Circulation, vol. 94, no. 3, pp. 258–265, 1996. View at Publisher · View at Google Scholar · View at Scopus
  90. K. K. Koh, M. J. Quon, S. H. Han et al., “Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients,” Circulation, vol. 110, no. 24, pp. 3687–3692, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. N. Suksomboon, N. Poolsup, and T. Prasit, “Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes,” Journal of Clinical Pharmacy and Therapeutics, vol. 37, no. 3, pp. 319–327, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. P. A. Economides, A. Caselli, E. Tiani, L. Khaodhiar, E. S. Horton, and A. Veves, “The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 740–747, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. A. Keech, R. J. Simes, P. Barter et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” The Lancet, vol. 366, no. 9500, pp. 1849–1861, 2005. View at Google Scholar